PCN103 Direct Medical Costs Associated with Multiple Myeloma in Chinese Patients: Estimations from China Public Health Insurance Claim Data  by Gao, SQ et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A447
should range between 52,061 to 67,684 euros. ConClusions: Ovarian cancer is 
a significant burden to the national health system and to society as a whole. The 
model’s results should provide a more precise quantification of both impacts.
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objeCtives: Cancer has been the first leading cause of death in Taiwan since 1982 
and its incidence is rising year by year. Disease burdens associated with cancers 
are substantial. This study aims to evaluate economic burdens of the top 10 cancers 
during 2003-2012 in Taiwan. Methods: Patients with diagnostic ICD-9-CM codes 
of lung, hepatic, colorectal, breast, oral, gastric, prostate, pancreatic, esophageal, 
and cervical cancer during 2003-2012 were identified as the study cases from the 
National Health Insurance Research Database. The prevalence‐based approach 
was employed to describe medical costs associated with the top 10 cancers. The 
productivity losses resulting from cancer deaths were also estimated by multiply-
ing potential life years lost due to the top 10 cancer deaths by average annual 
wage. Results: Total medical costs for all top 10 cancers were increasing, especially 
for lung and breast cancer. Total medical costs of colorectal cancer were the highest 
before 2008, while costs of lung and breast cancer have become dominant since 2008. 
Drug costs were increasing for most top 10 cancers, especially for lung, hepatic, and 
breast cancer. Inpatient costs accounted for the largest proportion of total medical 
costs for most top 10 cancers, except breast, prostate, and cervical cancers. The 
productivity losses incurred by lung, colorectal, breast, oral, and pancreatic cancers 
showed a slightly increasing trend. Hepatic, oral and lung cancers caused the top 
3 highest productivity losses for male, while breast, lung and colorectal cancer did 
for female. ConClusions: This study demonstrates an increasing trend in medical 
costs reimbursed by the National Health Insurance and mortality costs associated 
with the top 10 cancers. Out-of-pocket medical costs and non-medical costs associ-
ated with cancer treatment need to be included in the future to provide the overall 
picture of economic burdens of the top 10 cancers in Taiwan.
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objeCtives: Cervical cancer is the third most common cancer and the fourth can-
cer cause of death in women in Brazil. Given the high incidence, this disease has a 
considerable financial impact in the health budget.The study objective is to develop 
a cost-of-illness study to measure the cervical cancer social cost based in second-
ary data available for public access, in Brazil. Methods: The total cervical cancer 
social cost was calculated including direct medical costs (outpatient and inpatient), 
non-medical costs (caregiver day hospital), productivity loss due to inability of the 
patient to work, potential life-years lost and income loss due to premature death. 
Annual medical and non-medical costs were extracted from Brazilian official data-
base (DATASUS) based on the average annual costs of the last tree years (2012-2014). 
Inpatient productivity loss was calculated considering the mean length of stay 
reported in DATASUS and the Brazilian minimum wage. Outpatient productivity 
loss was calculated considering that patient would take one to fifteen days off. 
Income loss due to premature death was measured subtracting the Brazilian life 
expectancy by the age of death, also reported in DATASUS, and multiplying by the 
Brazilian annual average wage reported by Brazilian Institute of Geography and 
Statistics. International Classification of Diseases (ICD-10) codes considered in this 
analysis wereC358 and C359. Results: Cervical cancer annual direct and indirect 
cost is BRL 71 millions (outpatient cost: BRL44,608,394; inpatient cost including 
caregiver day hospital: BRL23,697,642; productivity loss (range): BRL7,880,390-
BRL20,146,696). Besides, BRL917 million was annually spent with income loss due 
to premature death. The total potential life-years lost was estimated in 33.898 
years. ConClusions: The results reveal that the cervical cancer cost is high in 
Brazil. Despite these results presented are an approximation of the real disease cost, 
it can be a useful data to improve health management practices and public policies.
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objeCtives: To estimate direct medical costs associated with multiple myeloma (MM) 
in publically insured Chinese patients. Methods: China Health Insurance Research 
Association (CHIRA) claim data containing patients randomly selected from publically 
insured urban residents and workers across China was used to identify patients with 
MM and their insurance claim records in 2013. The pattern of prescribed medica-
tions in the identified patients was used to determine the treatment settings for 
the estimations of direct medical costs. Generalized linear model (GLM) was used to 
assess the impact of treatment settings on the direct medical costs after full adjust-
ment of patient baseline demography, complications, and comorbidities. Results: 
The identified 522 patients with MM were stratified by treatment settings as induc-
tion treatment (n= 172), stem cell transplantation (SCT) (n= 7), first-line treatment 
(n= 186), second-line treatment (n= 71), and palliative care (n= 86). The total medical 
costs associated with treatment settings were RMB 69,126 for induction treatment, 
RMB 102,250 for SCT, RMB 77,871 for first-line treatment, RMB 31,193 for second-line 
treatment, and RMB 23,127 for palliative care, respectively (1 RMB = 0.16 US$). Based 
on the multivariate GLM regression analysis, living in central cities (coefficient 0.319, 
p= 0.042), treatment settings prior to palliative care (induction treatment: coefficient 
1.150, p< 0.001; SCT: coefficient 1.804, p< 0.001; first-line treatment: coefficient 1.062, 
objeCtives: Although the economic burden of brain tumors is potentially impor-
tant, little is known about the cost of these cancers in Canada. The objective of 
this study was to estimate the current economic burden associated with primary 
brain cancers in Canada. Methods: We used a prevalence-based cost-of-ill-
ness framework to estimate the annual cost due to primary brain tumors in the 
Canadian population. In order to retrieve clinical epidemiological and healthcare 
resources utilization data, relevant studies were identified with MEDLINE and 
EMBASE databases and Canadian Cancer statistics databases were consulted. The 
analysis was carried out from a societal perspective. Costs were extracted and 
converted to 2015 prices using the Canadian health component of the consumer 
price index. For each cost category, the estimated quantity for each resource was 
multiplied by the unit cost and then summed to get the total costs attributable to 
brain tumors in Canada. Results: Prevalence of primary brain tumors in Canada 
was estimated to 2,289 prevalent cases. Costs related to productivity losses for 
primary brain tumors represented 46% of the total costs. Direct costs were esti-
mated to 54% of the total costs, of which the costs associated with chemotherapy 
represented 52% of all direct costs, while hospitalization, imagery, medical vis-
its, radiotherapy, surgery and concomitant treatments represented 30%, 5%, 5%, 
4%, 3% and 1% of all direct costs respectively. The total cost of brain tumors in 
Canada was estimated at CAN$321,119,700 and the average cost per patient was 
CAN$140,288. ConClusions: The primary brain cancers are scarce but have high 
societal and economic impacts. This economic burden of primary brain cancers 
provides a comprehensive overview of the costs associated with these conditions.
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objeCtives: Economic evaluation is increasingly important in appraisal of innova-
tions in oncology, requiring accurate costing estimations. The MELISSA study aimed 
at assessing hospitalization costs of metastatic melanoma in France. Methods: 
A retrospective cohort analysis from French Medical Information System Program 
(PMSI, “Programme de Médicalisation des Systèmes d’Information”) for years 2011-
2013 was conducted. The study population consisted of all treatment naïve, incident 
adult patients hospitalized with metastatic melanoma diagnosed from 1 Jan 2011 
with follow-up until 31 Dec 2013 or death, whichever occurred first. Melanoma diag-
nosis and metastatic status was obtained using ICD-10 classification (melanoma: 
C43, metastatic status: C77, C78, C79). Patients were allocated to pre-progression and 
post-progression health states of the disease using progression markers, defined 
with clinical experts as the occurrence of either new or brain metastases, pallia-
tive care, or occurrence of both palliative care and brain metastasis or treatment 
switch, identified by specific ICD-10 code. Mean annual and monthly hospitaliza-
tion costs (primary objective) per patient were estimated using French tariffs and 
production costs, adjusting for annual deaths in both inpatient and outpatient 
settings. Secondary objectives consisted of mean annual/monthly costs of chemo-
therapies/immunotherapies, treatments-associated clinical events, palliative care 
and transportation. Results: The cohort enrolled 8,862 patients. There were 7,332 
patients (53% male) in pre-progression (26,843 hospital stays), 5,062 patients (56% 
male) in post-progression (36,425 hospital stays), and 3,479 hospital deaths. Costs 
expressed as mean annual production costs/patient-year were in pre-progression: 
4,973€ for hospitalization, 23,047€ for chemotherapies/immunotherapies, 4,177€ 
for clinical events and 619€ for transportation. In post-progression: 32,320€ for 
hospitalization, 17,884€ for chemotherapies/immunotherapies, 8,827€ for clinical 
events, 19,894€ for palliative care and 2,536€ for transportation. ConClusions: In 
metastatic melanoma in France, treatment costs accounted for the highest share. 
Except treatments, disease progression was associated with a tangible increase of 
hospitalization and other costs. These estimated hospital costs will be useful to 
populate cost-effectiveness models.
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objeCtives: Ovarian cancer is considered a rare disease but with a high mortality 
rate in women. Among women is the 5th most common cancer in Spain and the 
2nd most frequent gynecological malignant tumour. With a prevalence of 0.011% 
and a 0.007% incidence, it is the sixth leading cause of cancer death when com-
pared to all other cancers and the second of the gynecological cancer in Spain. The 
OvarCost study’s main objective is to estimate ovarian cancer’s burden of disease in 
Spain. The study’s secondary objective is to carry out a literature review regarding 
the disease. Methods: A Markov model was executed via the social perspective 
(direct, health and non-health related, and indirect costs) within a 10 year time 
horizon while taking into account disease prevalence, incidence and mortality. 
The model focused on epithelial ovarian cancer, and all four disease stages were 
taken into account. The data resulted from a literature review, later validated via 
a Delphi round and a physical meeting with an ovarian cancer multidisciplinary 
expert panel. Results: The total cost of cancer in Spain is 9,258 million euros, of 
which 4,224MM correspond to direct health costs (46%) and 5,033MM (54%) to direct 
costs not related to health and indirect costs. Thus, given this data and taking into 
account prevalence data at 1 and 5 years, where ovarian cancer accounted for 1.5% 
and 1.4%, respectively, of total cancers in Spain, our model’s results theoretically 
should range from 138-631 million euros, respectively. Prevalence is 2,633 and 9,322 
patients for 1 and 5 years, respectively. These results amount to a cost per patient 
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(UK) to € 77,854 (China) per quality adjusted life years (QALY) and € 37,361 per life 
years gained (LYG)(Europe and Canada). One French study showed an improvement 
in survival of 4 months between 2004 and 2012, with an ICER of € 54,355 per LYG, 
due to an increased use of temozolomide and bevacizumab. ConClusions: The 
literature on the cost of treatment and follow up of glioblastoma patients and on the 
cost-effectiveness of treatment modalities used in glioblastoma is scarce. Wide vari-
ations in cost are reported, probably reflecting the variation in health care systems.
PCN107
a systEmatiC litEraturE rEviEw of ECoNomiC BurdEN of 
myElofiBrosis
Sly IE1, Yang Y2, Lee D1
1BresMed, Sheffield, UK, 2Baxalta, Inc., Cambridge, MA, USA
objeCtives: To characterise the economic burden of myelofibrosis and associated 
areas of unmet need. Methods: A systematic literature review was performed for 
world-wide cost-effectiveness, cost and resource studies published between January 
2004 and September 2014. Databases included MEDLINE, MEDLINE In-process, 
EconLit, EMBASE and the Cochrane Library, as well as HTA websites. Results: The 
search identified 261 cost-effectiveness and 231 cost and resource papers. Following 
two rounds of assessment, two and eight studies, respectively, were included. 
Bennett et al., 2013, reported a substantial rise in total costs from USD10,523 in the 
year prior to diagnosis to USD51,654 in the year after diagnosis. A lifetime model 
developed by El Ouagari et al., 2012, (based on COMFORT-II data) predicted lifetime 
costs of CAD494,859 and CAD421,755 for ruxolitinib and best available therapy (BAT), 
respectively. The model calculated high indirect costs due to employment absentee-
ism for patients taking ruxolitinib (CAD71,848) and BAT (CAD96,458), indicating high 
burden for patients and society. Bennett et al. reported that costs were 85% greater in 
patients with previous anaemia treatment, including transfusions. Vekeman et al., 
2015, reported that 18% of transfusion-dependant patients received iron chelation 
therapy, with significantly higher monthly pharmacy costs vs. those without (mean 
difference: $1,426, p= 0.004). El Ouagari et al. predicted lifetime transfusion costs of 
CAD18,299 for patients taking ruxolitinib and CAD13,456 for those on BAT, suggest-
ing that patients treated with ruxolitinib may experience worsening of anaemia. 
This is consistent with COMFORT-I data, which showed that transfusion-dependant 
ruxolitinib patients increased from 25% at baseline to 40% at Weeks 8-12 (Pardanani 
and Tefferi, 2014; not identified via this search). ConClusions: Myelofibrosis leads 
to significant direct costs for health systems and substantial absenteeism costs for 
patients. Despite the available treatments, patients with disease and treatment 
emergent cytopenias and transfusion dependency require additional medical man-
agement, further augmenting the economic burden.
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objeCtives: To estimate the life time CoD in metastatic colorectal cancer (mCRC) 
patients who have progressed after standard therapies, in Turkish setting. Methods: 
A panel consisting of experts held a meeting to discuss the disease management in 
mCRC. They reviewed the literature and discussed the local clinical practices. All cost 
components (anticancer medications, routine care including inpatient and outpatient 
costs and adverse event management) were evaluated. The clinical/economic param-
eters were entered as inputs of a cohort partition model mimicking the follow-up of 
patients till death. Mid-2015 local prices for medications and procedures were used as 
sources. Mid-2015 EUR currency rate (2.9274TL/EUR) was used. Results: Percentages 
of patients according to the pharmaceuticals for anticancer treatment were as follows: 
capecitabine 85%, bevacizumab 35%, 5-FU+bevacizumab 12.5%, Mod-FOLFIRINOX 7.5% 
and raltitreksed 1.5%. Other pharmacologic treatment included medications related 
with gastrointestinal symptoms (antacid, anti-diarrheal, anti-emetic), analgesics 
and opioids. Outpatient costs included oncologist visits, blood tests, imaging and 
palliative radiotherapy (in 5%). Adverse events evaluated included constitutional, 
skin, cardiac, pulmonary, gastrointestinal, blood/bone marrow, infectious, neuro-
logic and metabolic events. The components of life time CoD (2544EUR) were as fol-
lows: anticancer treatment (216EUR), other pharmaceuticals (95EUR), routine care 
(247EUR) (inpatient 120EUR + outpatients 127EUR) and adverse event management 
(5.5EUR). ConClusions: The most costly component of expenses in mCRC is anti-
cancer treatment followed by routine care costs. Especially off-label chemotherapy 
agents are constituted significant part of this routine care costs.
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objeCtives: To summarize the existing literature regarding the medical cost and 
cost-effectiveness associated with treatment and follow-up of pancreatic can-
cer. Methods: PubMed was used as search engine to retrieve publications in 
Medline, using the search terms “pancreatic cancer” AND “cost” with a publica-
tion date filter (from January 1st 2000 up to September 1st2014) and language filter 
(English). This search yielded 416 results of which 48 were relevant for this review. 
Cost were recalculated in Euros (€ ) using the June 5 2015 currency rate of $1 = € 0.8914, 
CA$1 = € 0.7131 and £1 = € 1.3667. Results: The medical cost from diagnosis to death 
of one or more stages of pancreatic cancer were reported in 8 studies conducted in 
USA (n= 3), Sweden (n= 3), Germany (n= 1) and Japan (n= 1). Four studies included 
p< 0.001; second-line treatment: coefficient 0.377, p= 0.019), pulmonary infection 
(coefficient 0.780, p< 0.001), and suppressed bone marrow function (coefficient 0.352, 
p= 0.047) were significantly associated with increased direct medical costs and urban 
resident insurance (coefficient -0.410, p< 0.001) was significantly associated with less 
direct medical costs. ConClusions: The direct medical costs associated with MM 
in publically insured Chinese patients varied substantially by treatment settings. 
Except treatment settings, complications, and comorbidities, the social economic sta-
tus associated with insurance type and residence city size have a substantial impact 
on public health resource utilization in Chinese patients with MM.
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objeCtives: Breast cancer screening has resulted in increased diagnosis of ductal 
carcinoma in situ (DCIS). Compared with other breast cancers, little is known about 
the cost of illness or quality of life burden associated with DCIS. Methods: A struc-
tured literature search strategy was developed for identifying DCIS cost and QOL data 
in three publication databases (PubMed, EMBASE, and the Cochrane Library). Primary 
and secondary search criteria were “Carcinoma, Intraductal, Noninfiltrating” or “DCIS” 
and “Quality of life” or “Costs” or “Resource use”, respectively. Publications for review 
were restricted to those published between 2004 and 2014 inclusive. Abstract screen-
ing was performed by a single reviewer, with included results checked for protocol 
alignment by two further reviewers. Results: In total, 585 articles were identified 
for review, of which 55 were duplicates between databases. Following abstract review, 
111 articles were retained for analysis. The majority of excluded articles were not 
specific to DCIS or did not report cost or QOL data. DCIS does not directly affect QOL. 
Anxiety caused by DCIS diagnosis is a key decrement to QOL, although its impact can 
be transient. Longer term impacts on body image and role limitation were apparent 
following surgical intervention. Evidence of QOL detriments due to DCIS treatment 
were identified. Use of post-surgical radiotherapy is increasing, and patients receiving 
lumpectomy plus radiotherapy had significantly lower ‘mental health’ (74.0 vs. 77.4) 
and ‘vitality’ (59.3 vs. 63.5) QOL than controls. There is little data on the cost burden 
of DCIS. Individual cost items were identified, with radiotherapy estimated at USD 
10,700 to 34,900. ConClusions: Anxiety about tumour recurrence and body image 
and treatment side effects are the major factors influencing patient QOL in DCIS. 
Adverse events and costs associated with DCIS treatments makes the choice of treat-
ment pathway important for both patients and healthcare providers.
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objeCtives: Cervical cancer, caused by oncogenic Human Papillomavirus (HPV) 
types, is in Croatia the tenth most common cancer in women and accounted for 106 
women deaths in 2012. The aim of this study was to evaluate the costs associated 
with the diagnostic and treatment of cervical cancer and cervical intraepithelial 
neoplasia in Croatia in 2012. Methods: Publicly available data on the costs related 
to cervical cancer and cervical intraepithelial neoplasia diagnostic and treatment 
were collected. The main sources for the number of cases were the Croatian Institute 
of Public Health Yearbook for 2012 and Croatian Cancer Registry data. For the unit 
cost, the list of Diagnosis-Related Groups codes was used. When country-specific 
information was unavailable, reference to international data was used. Total cost 
was calculated by multiplying the number of cases with unit cost. Only direct medi-
cal costs were taken into consideration, using governmental perspective. Results: 
In 2012, cervical cancer and cervical intraepithelial neoplasia amounted to a total 
cost of € 5,418,790.70. Papanicolaou (Pap) smear tests represent the major source of 
expenditure with a total cost of € 2,367,686.92. A total of 374,484 Pap smear tests were 
carried on in 2012, from which 7.3% were pathological. ConClusions: Cervical 
cancer and cervical intraepithelial neoplasia caused by high risk oncogenic HPV-
types represent an important health and economic burden in Croatia. The results 
of this analysis may be useful to assess the potential reduction in cost associated 
with HPV-related diseases if additional prevention strategies were implemented.
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objeCtives: To summarize the existing literature regarding the medical cost associ-
ated with treatment and follow-up of glioblastoma. Methods: PubMed was used 
as search engine to retrieve publications in Medline using the search terms “(glio-
blastoma) AND (cost)” with a publication date filter (from January 1st 2000 up to 
September 1st2014) and language filter (English). This search yielded 107 publica-
tions of which 14 were relevant for this review. Costs were recalculated in Euros 
(€ ) using the June 5 2015 currency rate of $1 = € 0.8914, CA$1 = € 0.7131 and 1£ = 
€ 1.3667. Results: Two studies calculated the average total medical cost of glioblas-
toma treatment including direct hospital centered costs from diagnosis to death 
and one study included healthcare payer perspective cost from diagnosis to two 
years of follow-up. The cost ranged between € 12,229 - € 43,894 (median: € 39,000). Two 
studies calculated the average cost of the combination of surgery and chemoradio-
therapy which varied from € 16,007 per patient in Canada to € 41,744 per patient in 
Switzerland. The addition of temozolomide to radiotherapy prolongs survival and 
improves quality of life. The incremental cost-effectiveness ratio (ICER) of temozo-
lomide plus radiotherapy as compared to radiotherapy alone ranged from € 49,054 
